PhotoPharmics: Funding, Investors & Team (Oct 2026)
PhotoPharmics is a medical device company in the clinical stage that is working on advanced treatments for neurodegenerative disorders by utilizing the eyes. The company is expanding its research to include other neurodegenerative diseases as well. In Parkinson's disease, PhotoPharmics has pioneered the use of specific light wavelengths and has successfully completed a key human clinical trial.
PhotoPharmics has raised $22.1M across 2 funding rounds on record, the most recent a Series B of $6.0M announced in Apr 2025.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
PhotoPharmics Company Profile and Key Stats
Latest funding round on record: Apr 2025.
PhotoPharmics Funding Rounds
PhotoPharmics raised $16.1M in an undisclosed round announced in Nov 2023.
1.4 years later, a Series B of $6.0M was announced in Apr 2025.
PhotoPharmics Founders and Leadership Team
Contact details for the PhotoPharmics team: 1 of 1 has an email address on file.
Start 14-day free trial →PhotoPharmics Funding Compared to Other Biotechnology Startups
PhotoPharmics' latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like PhotoPharmics in Biotechnology and Lehi
Companies Similar to PhotoPharmics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
PhotoPharmics Funding FAQs
What does PhotoPharmics do?
PhotoPharmics is a medical device company in the clinical stage that is working on advanced treatments for neurodegenerative disorders by utilizing the eyes. The company is expanding its research to include other neurodegenerative diseases as well. In Parkinson's disease, PhotoPharmics has pioneered the use of specific light wavelengths and has successfully completed a key human clinical trial.
How much funding has PhotoPharmics raised?
PhotoPharmics has raised $22.1M across 2 rounds on record. The most recent is a Series B of $6.0M announced in Apr 2025.
When did PhotoPharmics last raise funding?
PhotoPharmics' most recent funding round on record is a Series B of $6.0M, announced in Apr 2025.
Who founded PhotoPharmics?
FundedIQ lists Kent Savage (Founder) at PhotoPharmics.
Where is PhotoPharmics headquartered?
PhotoPharmics is based in Lehi, Utah, United States.
How many employees does PhotoPharmics have?
PhotoPharmics is in the 1-10 employee band.
How does PhotoPharmics' funding compare to other Biotechnology startups?
PhotoPharmics' latest round of $6.0M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's PhotoPharmics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for PhotoPharmics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.